Zometa Loss at Trial

A New Jersey state court gave Novartis a defense verdict in a jaw injury lawsuit in this mass tort claim.

The issue in this cases is largely about warnings: what did Novartis have to communicate to doctors about the risks of Zometa with respect to osteonecrosis of the jaw (ONJ). The jury, by a vote of 7-1 vote, said Novartis provided an adequate warning.

No matter how you slice these cases, they are tragedies. The plaintiff in this case was prescribed Zometa to protect her bones after breast cancer. Then, she developed ONJ. Just awful.